Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer
posted 26 mins
Shared 0 times
OncLive - Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive...
Long-Term KEYNOTE-426 Data Support Pembrolizumab/Axitinib as Frontline Standard in Advanced RCC
posted 1 hour
Shared 0 times
OncLive - Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from...
OncLive - Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung...
FDA Issues Complete Response Letter for Pembrolizumab/Lenvatinib in First-Line HCC
posted 2 hours
Shared 0 times
OncLive - The FDA has issued a complete response letter to Merck and Eisai stating that it will not approve the applications that are seeking the...
OncLive - Katherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer...
Systemic Therapies Improve Breast Cancer With Brain Metastases Management
posted 3 hours
Shared 0 times
OncLive - Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival...
COVID-19 Blood Clotting Cause Identified in Study Led by Yale Cancer Center Researchers
posted 4 hours
Shared 0 times
OncLive - One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and...
Dr. Accordino on Data From the PEARL Trial in HR+/HER2- Metastatic Breast Cancer
posted 5 hours
Shared 0 times
OncLive - Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast...
OncLive - Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation...
Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma
posted 6 hours
Shared 0 times
OncLive - OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and...
Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. @YaleCancer #gynca https://t.co/jbqRghdV9Q https://t.co/jbqRghdV9Q